Medexus Pharmaceuticals Inc. (TSE:MDP) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Medexus Pharmaceuticals Inc. (TSE:MDP) have been assigned an average rating of “Buy” from the seven research firms that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation, one has assigned a buy recommendation and four have given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is C$5.49.

Several research analysts have commented on the company. Raymond James raised Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price target on the stock in a research report on Wednesday, January 8th. Ventum Cap Mkts raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 17th. Stifel Nicolaus downgraded shares of Medexus Pharmaceuticals from a “buy” rating to a “hold” rating and reduced their price target for the company from C$6.00 to C$3.45 in a research report on Friday, February 7th. Stifel Canada downgraded shares of Medexus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. Finally, Leede Financial raised shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, January 22nd.

Medexus Pharmaceuticals Stock Performance

MDP opened at C$2.15 on Friday. Medexus Pharmaceuticals has a one year low of C$1.47 and a one year high of C$5.56. The stock has a market capitalization of C$48.13 million, a P/E ratio of 10.28 and a beta of 1.96. The business’s 50-day simple moving average is C$2.93 and its 200-day simple moving average is C$2.91.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.